Veracyte, Inc. (VCYT)
NASDAQ: VCYT · Real-Time Price · USD
47.60
+3.11 (6.99%)
May 28, 2026, 12:59 PM EDT - Market open
Veracyte Employees
Veracyte had 755 employees as of December 31, 2025. The number of employees decreased by 69 or -8.37% compared to the previous year.
Employees
755
Change (1Y)
-69
Growth (1Y)
-8.37%
Revenue / Employee
$717,540
Profits / Employee
$116,574
Market Cap
3.80B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 755 | -69 | -8.37% |
| Dec 31, 2024 | 824 | 9 | 1.10% |
| Dec 31, 2023 | 815 | 28 | 3.56% |
| Dec 31, 2022 | 787 | 26 | 3.42% |
| Dec 31, 2021 | 761 | 441 | 137.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ICON Public Limited Company | 40,100 |
| Charles River Laboratories International | 19,700 |
| RadNet | 9,276 |
| Qiagen | 5,700 |
| Sotera Health Company | 3,000 |
| NeoGenomics | 2,500 |
| GeneDx Holdings | 1,300 |
| Twist Bioscience | 979 |
VCYT News
- 1 day ago - Veracyte genomic test identifies breast cancer patients who can skip chemo - Reuters
- 6 days ago - Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings - Business Wire
- 6 days ago - OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer - Business Wire
- 8 days ago - Veracyte to Participate in Upcoming Investor Conferences - Business Wire
- 13 days ago - Veracyte’s TrueMRD Monitoring Test receives coverage from CMS - TheFly
- 13 days ago - Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer - Business Wire
- 21 days ago - Veracyte price target raised to $42 from $40 at Canaccord - TheFly
- 21 days ago - Veracyte price target raised to $52 from $48 at UBS - TheFly